このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Novonesis マネジメント

マネジメント基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Ester Baiget

最高経営責任者

€3.9m

報酬総額

CEO給与比率	33.3%
CEO在任期間	4.6yrs
CEOの所有権	n/a
経営陣の平均在職期間	3.4yrs
取締役会の平均在任期間	4yrs

経営陣の近況

Recent updates

CEO報酬分析

Novonesis の収益と比較して、Ester Baiget の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	€283m
Mar 31 2024	n/a	n/a	€332m
Dec 31 2023	€4m	€1m	€406m
Sep 30 2023	n/a	n/a	€430m
Jun 30 2023	n/a	n/a	€460m
Mar 31 2023	n/a	n/a	€487m
Dec 31 2022	€3m	€1m	€494m
Sep 30 2022	n/a	n/a	€460m
Jun 30 2022	n/a	n/a	€418m
Mar 31 2022	n/a	n/a	€416m
Dec 31 2021	€3m	€1m	€423m
Sep 30 2021	n/a	n/a	€427m
Jun 30 2021	n/a	n/a	€409m
Mar 31 2021	n/a	n/a	€389m
Dec 31 2020	€3m	€927k	€380m

報酬と市場: Esterの総報酬 ($USD 4.33M ) は、 Austrian市場 ($USD 4.52M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Esterの報酬は 20% 以上増加しましたが、会社の収益は過去 1 年間で 20% 以上減少しました。

CEO（最高経営責任者

Ester Baiget (53 yo)

4.6yrs

在職期間

€3,903,958

報酬

Ms. Ester Baiget serves as Chief Executive Officer and President of Novozymes A/S since joining on February 1, 2020. She serves as Member of Supervisory Board at Akzo Nobel N.V. since 2022. She served as t...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Ester Baiget	President & CEO	4.6yrs	€3.90m	データなし
Rainer Lehmann	Executive VP & CFO	less than a year	€858.60k	データなし
Anders Lund	Chief Operating Officer	less than a year	€1.03m	データなし
Claus Fuglsang	Chief Scientific Officer	4yrs	データなし	データなし
Tobias Bjorklund	Head of Investor Relations	no data	データなし	データなし
Tue Micheelsen	Vice President of Global Sales & Marketing	no data	データなし	データなし
Morten Rasmussen	Executive Vice President of People & Stakeholder Relations	3.4yrs	データなし	データなし
Tina Fano	Executive Vice President of Planetary Health Biosolutions	8.6yrs	€1.02m	データなし
Amy Byrick	Executive Vice President of Human Health Biosolutions	3.4yrs	データなし	データなし
Henrik Nielsen	Executive Vice President of Strategy & Integration	less than a year	データなし	データなし
Jacob Paulsen	Executive Vice President of Food & Beverage Biosolutions	less than a year	データなし	データなし
Peter Rosholm	Chief Executive Officer of Albumedix	8.7yrs	データなし	データなし

3.4yrs

平均在職期間

50yo

平均年齢

経験豊富な経営陣: NZYMの経営陣は経験豊富であると考えられます ( 3.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Jesper Brandgaard	Vice Chair of the Board	less than a year	データなし	データなし
Cornelis de Jong	Independent Chairman	4.6yrs	€239.07k	0.0011% € 320.3k
Kim Stratton	Independent Director	7.6yrs	€173.33k	データなし
Kasim Kutay	Director	7.6yrs	€107.73k	0.00023% € 68.2k
Heine Dalsgaard	Director	4.6yrs	€143.55k	0.00065% € 192.8k
Lise Kaae	Director	less than a year	データなし	データなし
Anders Knudsen	Employee Representative Director	11.6yrs	€71.77k	データなし
Sharon James	Independent Director	4.6yrs	€143.55k	データなし
Anne Breum	Employee Representative Director	3.5yrs	€71.77k	0.00013% € 38.6k
Preben Nielsen	Employee Representative Director	3.5yrs	€107.73k	0.000090% € 26.7k
Jens Obro	Employee Representative Director	3.5yrs	€71.77k	0.00012% € 35.6k
Morten Otto Sommer	Independent Director	2.5yrs	€137.51k	0.00022% € 65.2k

4.0yrs

平均在職期間

60yo

平均年齢

経験豊富なボード: NZYMの取締役会は経験豊富であると考えられます ( 4年の平均在任期間)。

Novonesis マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Novozymes A/S Announces Board Appointments

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Novozymes A/S Announces Change to the Executive Leadership Team

Independent Chairman recently bought €135k worth of stock

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Less than half of directors are independent

Recent updates

First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023)

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Full year 2023 earnings released

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

New minor risk - Share price stability

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings released

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Second quarter 2023 earnings released: EPS: kr.2.19 (vs kr.2.92 in 2Q 2022)

Novozymes A/S Announces Change to the Executive Leadership Team

First quarter 2023 earnings released: EPS: kr.2.83 (vs kr.3.00 in 1Q 2022)

Upcoming dividend of kr.6.00 per share at 1.7% yield

Independent Chairman recently bought €135k worth of stock

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Investor sentiment deteriorated over the past week

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Third quarter 2022 earnings released

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Second quarter 2022 earnings released: EPS: kr.2.92 (vs kr.2.85 in 2Q 2021)

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

First quarter 2022 earnings released: EPS: kr.3.00 (vs kr.3.17 in 1Q 2021)

Less than half of directors are independent

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Upcoming dividend of kr.5.50 per share

Full year 2021 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Revenue Guidance for 2022

Novozymes A/S (CPSE:NZYM B) completed the acquisition of a 60% stake in Synergia Life Sciences Pvt. Ltd. for DKK 1 billion.

Third quarter 2021 earnings released

Second quarter 2021 earnings released

Novozymes A/S Provides Earnings Guidance for the Full Year 2021

First quarter 2021 earnings released: EPS kr.3.17 (vs kr.2.89 in 1Q 2020)

Novozymes A/S Reaffirms Sales Guidance for the Year 2021

Univar Solutions and Novozymes® Partner to Bring Innovative, Sustainable Biotechnology Products to Customers in the United States and Canada

Novozymes Acquires Data Science Platform of Biota to Strengthen Microbiome R&D Capabilities in Probiotic Development

Novozymes A/S (CPSE:NZYM B) acquired the Microbiome R&D Team and Data Science Platform from Biota Technology, Inc.

New 90-day high: €51.50

Novozymes A/S Announces Executive Appointments, Effective April 2021

Full year 2020 earnings released

Revenue misses expectations

Fmc Corporation Collaborates with Novozymes A/S to Co-Develop Enzyme Solutions

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Microbiome Labs.

Novozymes A/S (CPSE:NZYM B) entered into an agreement to acquire Microbiome Labs for $250 million

New 90-day low: €45.33

Novozymes A/S to Report Fiscal Year 2020 Results on Jan 01, 2021

マネジメント基準チェック /34